SAB Biotherapeutics (NASDAQ:SABS) Now Covered by Analysts at Brookline Capital Management

Brookline Capital Management began coverage on shares of SAB Biotherapeutics (NASDAQ:SABSFree Report) in a report issued on Friday, Benzinga reports. The firm issued a buy rating and a $8.00 price target on the stock.

Other analysts have also recently issued reports about the stock. HC Wainwright reissued a buy rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday, May 21st. Chardan Capital reissued a buy rating and set a $25.00 price target on shares of SAB Biotherapeutics in a research report on Tuesday, May 21st.

Check Out Our Latest Stock Analysis on SABS

SAB Biotherapeutics Price Performance

SABS opened at $2.98 on Friday. SAB Biotherapeutics has a 1 year low of $2.36 and a 1 year high of $10.50. The company’s 50 day simple moving average is $3.82 and its 200 day simple moving average is $3.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.65 and a quick ratio of 5.65.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pathstone Family Office LLC purchased a new position in SAB Biotherapeutics in the third quarter valued at about $319,000. RTW Investments LP acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $6,310,000. BVF Inc. IL purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $6,310,000. Finally, Commodore Capital LP acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth $1,259,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

Featured Stories

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.